Endoscopy 2014; 46(06): 507-512
DOI: 10.1055/s-0034-1365495
Innovations and brief communications
© Georg Thieme Verlag KG Stuttgart · New York

Suppression of stent-induced tissue hyperplasia in rats by using small interfering RNA to target matrix metalloproteinase-9

Eun-Young Kim
1  Medical Device Development Center, Osong Medical Innovation Foundation, Chungbuk, Korea
,
Ji Hoon Shin
2  Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
,
Ho-Young Song
2  Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
,
Jin Hyung Kim
2  Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
,
Edward W. Lee
3  Department of Radiology, UCLA Medical Center, Los Angeles, USA
,
Won Jong Kim
4  Department of Chemistry, Polymer Research Institute, Pohang University of Science and Technology, Pohang, Korea
,
Dong-Ho Shin
2  Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
,
Heuiran Lee
5  Department of Microbiology, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Seoul, Korea
› Author Affiliations
Further Information

Publication History

submitted 27 July 2013

accepted after revision 09 January 2014

Publication Date:
25 April 2014 (eFirst)

Background and study aims: We evaluated the efficacy of small interfering RNA (siRNA) in targeting matrix metalloproteinase (MMP-9) to suppress stent-induced tissue hyperplasia in a rat esophageal model.

Methods: The silencing effect of the candidate siRNA (termed (MMP-9 siRNA) was evaluated in 9 L rat glial cells. Four groups of rats (n = 10, each group) were used: Eso-S, stent insertion only, comparison; Eso-R, stent insertion plus treatment with MMP-9 siRNA complexed with Chol-R9 for delivery, experimental; Eso-P, stent insertion plus treatment with pCMV-luc complexed with Chol-R9, for confirmation of Chol-R9 delivery effect; and Eso-N, no stent insertion and no treatment, controls. All rats were sacrificed at 3 weeks. The therapeutic efficacy of the MMP-9 siRNA/Chol-R9 complex was assessed.

Results: The most potent MMP-9 siRNA was selected. Compared with the Eso-S group, the Eso-R group showed significantly less tissue hyperplasia with a lower percentage of granulation tissue and smaller granulation tissue area, and also significantly lower MMP-9 level.

Conclusions: MMP-9 siRNA/Chol-R9 is effective for inhibiting stent-induced tissue hyperplasia in a rat esophageal model.